March 19, 2019
A new study published in Lupus showed that mycophenolate mofetil (MMF) is comparable in effectiveness to the standard treatment intravenous cyclophosphamide (IVCYC) for lupus nephritis in pediatric patients.
The study compared response to treatment, kidney damage, time needed to result in inactive lupus nephritis and disease flares. Of the 51 patients studied, all of whom were 16 years old or under, 67 percent received MMF and 33% received IVCYC.
This was the largest study investigating treatments for lupus nephritis in children, and showed that treatment with MMF is comparable to standard treatment with IVCYC.